Ginkgo Bioworks Holdings Inc. Class A (DNA)
$6.89
$-0.06
(-0.86%)
As on 04-Sep-2026 13:41EDT
Market cap
$468 Mln
Revenue (TTM)
$112 Mln
P/E Ratio
--
P/B Ratio
1.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-162 Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.8
-
Debt to Equity
0
-
Book Value
$6.6
-
EPS
$-5
-
Face value
--
-
Shares outstanding
55,383,808
5 Years Aggregate
CFO
$-982.01 Mln
EBITDA
$-4,847.20 Mln
Net Profit
$-5,082.46 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ginkgo Bioworks Holdings Inc. Class A (DNA)
| -17.1 | -22.9 | -21.1 | -39.2 | -57.5 | -55.6 | -- |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Ginkgo Bioworks Holdings Inc. Class A (DNA)
| -15.4 | -85.2 | 0.0 | -79.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ginkgo Bioworks Holdings Inc. Class A (DNA)
|
6.9 | 468.0 | 111.9 | -290.8 | -263.7 | -62.6 | -- | 1.1 |
| 84.8 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.0 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 355.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 118.2 | 9,718.7 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.6 | |
| 541.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 |
Shareholding Pattern
View DetailsAbout Ginkgo Bioworks Holdings Inc. Class A (DNA)
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and... development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Read more
-
Founder, CEO & Director
Dr. Jason Kelly
-
Founder
Mr. Thomas Knight Jr.
-
Headquarters
Boston, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Ginkgo Bioworks Holdings Inc. Class A (DNA)
What is the current share price of Ginkgo Bioworks Holdings Inc Class A (DNA) Today?
The share price of Ginkgo Bioworks Holdings Inc Class A (DNA) is $6.89 (NYSE) as of 04-Sep-2026 13:41 EDT. Ginkgo Bioworks Holdings Inc Class A (DNA) has given a return of -57.54% in the last 3 years.
What is the current PB & PE ratio of Ginkgo Bioworks Holdings Inc Class A (DNA)?
Since, TTM earnings of Ginkgo Bioworks Holdings Inc Class A (DNA) is negative, P/E ratio is not available.
The P/B ratio of Ginkgo Bioworks Holdings Inc Class A (DNA) is 1.11 times as on 04-Sep-2026, a 79 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.47 |
0.91 |
2024 |
-0.93 |
0.71 |
2023 |
-0.09 |
0.08 |
2022 |
-0.04 |
0.05 |
2021 |
-0.17 |
0.21 |
What is the 52 Week High and Low of Ginkgo Bioworks Holdings Inc Class A (DNA)?
The 52-week high and low of Ginkgo Bioworks Holdings Inc Class A (DNA) are Rs 17.58 and Rs 5.37 as of 05-Sep-2026.
What is the market cap of Ginkgo Bioworks Holdings Inc Class A (DNA)?
Ginkgo Bioworks Holdings Inc Class A (DNA) has a market capitalisation of $ 468 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Ginkgo Bioworks Holdings Inc Class A (DNA)?
Before investing in Ginkgo Bioworks Holdings Inc Class A (DNA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.